Potential Candidates against COVID-19 Targeting RNA-Dependent RNA Polymerase: A Comprehensive Review

(E-pub Ahead of Print)

Author(s): Neetu Agrawal*, Ahsas Goyal

Journal Name: Current Pharmaceutical Biotechnology

Become EABM
Become Reviewer
Call for Editor


Due to the extremely contagious nature of SARS-COV-2, it presents a significant threat to humans worldwide. A plethora of studies are going on all over the world to discover the drug to fight SARS-COV-2. One of the most promising targets is RNA-dependent RNA polymerase (RdRp), responsible for viral RNA replication in host cells. Since RdRp is a viral enzyme with no host cell homologs, it allows the development of selective SARS-COV-2 RdRp inhibitors. A variety of studies used in silico approaches for virtual screening, molecular docking, and repurposing of already existing drugs and phytochemicals against SARS-COV-2 RdRp. This review focuses on collating compounds possessing the potential to inhibit SARS-COV-2 RdRp based on in silico studies to give medicinal chemists food for thought so that the existing drugs can be repurposed for the control and treatment of ongoing COVID-19 pandemic after performing in vitro and in vivo experiments.

Keywords: COVID-19, SARS-COV-2, in silico, molecular docking, RdRp, RNA-dependent RNA polymerase.

Rights & PermissionsPrintExport Cite as

Article Details

Published on: 20 April, 2021
(E-pub Ahead of Print)
DOI: 10.2174/1389201022666210421102513
Price: $95

Article Metrics

PDF: 241